Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
XP-105 by Xynomic Pharmaceuticals for Breast Cancer: Likelihood of Approval
XP-105 is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase...